NIL

根据《中信建投证券股份有限公司关于浙江圣达生物药业股份有限公司2025年持续督导年度报告书》，报告内容为保荐人对上市公司持续督导的合规执行情况、信息披露审查、公司治理、募集资金使用及相关承诺履行等常规事项的年度汇报。报告明确指出浙江圣达生物药业股份有限公司及其控股股东、实际控制人、董事、高级管理人员在持续督导期间未发生违法违规、未履行承诺、未出现应报告的重大事项，募集资金管理与使用符合规定，信息披露真实、准确、完整、及时，并未发现重大异常或需要报告的事项。整体内容未涉及任何可能影响公司股价的重大事件或敏感信息。

According to the “Annual Report of Sustained Supervision by CITIC Securities for Zhejiang Shengda Biopharmaceutical Co., Ltd. in 2025,” the report is a routine annual compliance review covering sponsor duties, company governance, information disclosure, use of raised funds, and fulfillment of commitments. The report clearly states that Zhejiang Shengda Biopharmaceutical Co., Ltd. and its controlling shareholders, actual controllers, directors, and senior management did not violate regulations, failed to fulfill commitments, or have any material events to report during the supervision period. Fund management and usage were compliant, information disclosure was accurate and timely, and no significant abnormalities or reportable events were found. The document does not contain any information that would be considered price-sensitive or likely to affect the share value.

Disclaimer: The above summary is based solely on the content of the cited regulatory report. It does not constitute investment advice. Investors should always conduct their own due diligence and consult professional advisors before making investment decisions.

View 圣达生物 Historical chart here